Corcept Therapeutics' stock price surged about 228% from $35.69 on March 4 to $117.17 by August 18, significantly increasing the value of President Donald Trump's disclosed position in the company. The rally was driven by FDA backing for Corcept's drug relacorilant, positive clinical trial results showing a 35% reduction in death risk, and Trump's announcement of continued zero-percent tariffs on imported generic drugs until 2026. These factors helped Corcept's market cap reach $12.67 billion and pushed its shares higher amid favorable regulatory and trade developments.
TPG RE Finance Trust (TRTX) is rated Sell due to its inability to cover dividends with distributable earnings, reporting $0.23 per share against a $0.24 dividend in Q2. Despite higher loan balances, net interest income dropped 5.9% year-over-year, pr...
Leidos and investment firm Altaris have completed their joint venture to create a US-based company under the Analogic brand, combining security screening technologies for airports, borders, and critical infrastructure worldwide. Leidos retains a sign...
MicroStrategy, now rebranded as Strategy, purchased only 334 Bitcoin last week for $28.7 million, a much smaller amount compared to previous weeks. Instead, it spent $176.3 million buying back its preferred stock, which pays a 12% dividend, signaling...
Once Upon a Farm has expanded its product line with new organic Electrolyte Blends designed to support hydration and electrolyte balance in active children. These pouches use real food ingredients like fruits, veggies, coconut water, and sea salt, of...
EPAM Systems has introduced a new AI service designed to support next-generation frontier AI models in handling complex enterprise workflows more reliably. This offering leverages EPAM's extensive experience and partnerships with leading AI labs like...
